Latest Breaking News On - Nareg sagherian - Page 3 : comparemela.com

Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses - Intercept Pharma (NASDAQ:ICPT)

Measures reinforce Company's ability to drive growth in PBC business and continue developing innovative new medicines Company to discontinue all NASH-related investment and reduce workforce by approximately one third

United statesJerry dursoNareg sagherianKaren prebleGlobal corporate communicationsDrug administrationInternational normalized ratioIntercept pharmaceuticals incCompany on twitterChief executive officerSerious liverLiver congressImportant safety informationNarrow therapeuticBile salt effluxFull prescribing information

Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Region flamandeUnited statesFrederik nevensM michelle berreyNareg sagherianKaren prebleWarfarinthe international normalized ratioResearch developmentGlobal corporate communicationsProfessor at university hospitals ku leuvenCompany on twitterIntercept pharmaceuticals incEuropean associationChief medical officerUniversity hospitalsFixed dose combinationintercept

Intercept Pharma (ICPT) Receives CRL for Obeticholic Acid

Intercept Pharma (ICPT) Receives CRL for Obeticholic Acid
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jerry dursoKaren prebleNareg sagherianCompany new drug applicationGlobal corporate communicationsIntercept pharmaceuticals incDrug administrationEtthe companyCompany on twitterIntercept pharmaceuticalsComplete response letterNew drug applicationChief executive officerLooking statementsthisExecutive directorGlobal investor

Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC

Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesVaclav hejdaM michelle berreyFrederik nevensNareg sagherianAntonio civitareseCheng zouLynda szczechAlexandre louvetKaren prebleIntercept pharmaceuticals incResearch developmentCompany on twitterWarfarinthe international normalized ratioGlobal corporate communicationsWall street

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,. | June 7, 2023

United statesAntonio civitareseKaren prebleFrederik nevensAlexandre louvetLynda szczechNareg sagherianM michelle berreyCheng zouVaclav hejdaResearch developmentGlobenewswire incCompany on twitterIntercept pharmaceuticals incEuropean association for the studyGlobal corporate communications